By admin 
Including the Cancer Research Institute (CRI) in one’s will is a profoundly personal and impactful decision, serving as a cornerstone in the global effort to create a world immune to cancer. This act of philanthropic foresight ensures that the pioneering work in immunotherapy, a revolutionary field transforming cancer treatment, receives sustained support. The motivations behind such generosity are as diverse as the donors themselves, often stemming from deeply personal experiences, a profound appreciation for scientific advancement, or a commitment to making a lasting difference beyond one’s lifetime. Many supporters cite direct benefits from lifesaving immunotherapy treatments received by themselves or their loved ones, while others are inspired by CRI’s enduring legacy as a trailblazer, consistently pushing the boundaries of scientific discovery. All who choose to make a gift to CRI through their estate understand the critical nature of this work in humanity’s ongoing battle against cancer.
The Strategic Importance of Legacy Giving in August’s Make-A-Will Month
The month of August, annually designated as Make-A-Will Month, serves as a timely reminder for individuals to review or establish their estate plans. This period offers a unique opportunity to consider how one’s legacy can contribute to causes that resonate deeply, such as propelling immunotherapy progress. Among the various avenues for generous giving to the Cancer Research Institute, a legacy gift, made through a will or living trust, stands out as a simple, flexible, and immensely powerful mechanism. These planned gifts represent a long-term investment in the future of cancer treatment, providing the stable, predictable funding necessary for complex, multi-year research initiatives.
Katherine Pooser, Director of Planned Giving at CRI, underscores the confidence donors can place in their contributions. "When a person generously gives through a will or living trust, they can do so with confidence knowing CRI regularly receives recognition from third-party assessors for its good governance and fiscal responsibility," Pooser stated. This assurance is not merely a formality; it is a critical factor for donors entrusting their assets to an organization for future impact. CRI’s consistent achievement of top ratings, such as a 100% four-star charity rating from organizations like Charity Navigator, signifies an unwavering commitment to transparency, accountability, and efficient use of funds. These accolades validate CRI’s operational integrity, assuring donors that their intended impact will be realized with the utmost diligence and ethical stewardship. Pooser further emphasized the tangible difference these gifts make: "Supporters can also be confident that their gift makes a real difference. Bequests of every size come together to make up a substantial part of the funding that drives the next wave of immunotherapy developments." This collective power of individual legacy gifts, regardless of their monetary value, coalesces into a formidable financial engine for scientific breakthroughs.
CRI’s Enduring Legacy and the Evolution of Immunotherapy
The Cancer Research Institute’s journey began in 1953, at a time when the concept of harnessing the body’s own immune system to fight cancer was largely dismissed by the mainstream medical community. Founded on the then-revolutionary premise that the immune system held the key to defeating cancer, CRI embarked on a mission to fund and foster research in immunology. For decades, CRI stood as a solitary beacon, supporting pioneering scientists who dared to explore this unconventional path, even as traditional treatments like chemotherapy and radiation dominated the landscape.
The history of immunotherapy itself is a testament to perseverance and visionary thinking. Early attempts, such as William Coley’s use of bacterial toxins in the late 19th century, showed glimpses of the immune system’s potential but lacked scientific understanding and reproducibility. The mid-20th century saw advancements in basic immunology, yet a direct link to cancer therapy remained elusive. It wasn’t until the late 20th and early 21st centuries that the field truly began to accelerate, with CRI playing a pivotal role in funding foundational research that led to major breakthroughs. The identification of immune checkpoints, the development of monoclonal antibodies to block them (leading to drugs like pembrolizumab and nivolumab), and the advent of CAR T-cell therapy are all built upon decades of basic immunological research, much of which was supported by organizations like CRI. The awarding of the Nobel Prize in Physiology or Medicine in 2018 to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation served as a global affirmation of immunotherapy’s transformative power, a validation of the path CRI had championed for over half a century.
CRI’s role as a pioneer extends beyond mere funding; it involves actively shaping the research landscape. Through its various programs, including postdoctoral fellowships, clinician-scientist awards, and the highly competitive CLIP (Clinic and Laboratory Integration Program) Investigator grants, CRI identifies and nurtures the brightest minds in immunology and cancer research. This strategic investment in human capital ensures a continuous pipeline of innovative ideas and dedicated scientists committed to understanding and manipulating the immune system to conquer cancer.
The Tangible Impact: From Lab Bench to Patient Bedside
Generous bequests are not abstract donations; they are the lifeblood that enables CRI-funded scientists to pursue rigorous immunotherapy research, ultimately benefiting countless cancer patients worldwide. The scope of this research is vast and increasingly specialized, reflecting the complex nature of cancer and the immune system. For instance, some CRI-funded scientists delve into the intricate relationship between sensory neurons and lung cancer, exploring how nerve signals might influence tumor growth or immune responses within the lung microenvironment. Understanding these neural-immune interactions could unlock novel therapeutic targets.
In another cutting-edge area, researchers are leveraging artificial intelligence (AI) approaches to analyze T cells, the immune system’s primary warriors against cancer. AI and machine learning algorithms can process vast datasets from patient samples, identifying subtle patterns in T-cell behavior, gene expression, and spatial organization within tumors that human analysis might miss. This deeper understanding can lead to more effective strategies for engineering T cells for therapy, predicting patient response to existing immunotherapies, or designing personalized treatment regimens. The scientists engaged in these diverse, high-impact projects are profoundly appreciative of CRI’s support, acknowledging that such assistance is made possible only through the unwavering commitment of the broader community to immunotherapy.
Dr. Lloyd Bod, a CRI Thompson Family Foundation CLIP Investigator and assistant professor of medicine at Massachusetts General Hospital, eloquently articulates the value of this support. "Being a CRI CLIP Investigator is an honor, and not only provides crucial funding, but also connects me with a network of researchers dedicated to making groundbreaking discoveries in immunotherapy," Dr. Bod stated. He emphasized that this support fosters "a commitment to pursuing innovative science that can lead to life-saving therapies for patients worldwide." The "crucial funding" mentioned by Dr. Bod often enables researchers to conduct high-risk, high-reward studies that traditional government grants might deem too speculative in their early stages. These pilot projects, if successful, can generate the preliminary data needed to secure larger grants, thereby accelerating the pace of discovery. Moreover, the network of researchers facilitated by CRI fosters collaborative environments, allowing for the cross-pollination of ideas and expertise, which is vital in a field as complex and rapidly evolving as immunotherapy.
Donor Motivations and the Power of a Lasting Legacy
The decision to include CRI in an estate plan is often driven by a confluence of powerful motivations. For many, it is a deeply personal act of gratitude. Having witnessed the miraculous efficacy of immunotherapy in their own lives or the lives of loved ones, these donors are compelled to "pay it forward," ensuring that future generations have access to these life-extending and often curative treatments. The emotional resonance of seeing a loved one recover from a previously untreatable cancer due to immunotherapy is a profound catalyst for such generosity.
Beyond personal experience, a significant number of donors are driven by an intellectual appreciation for scientific progress. They recognize CRI’s historical role as a pioneer and its ongoing commitment to pushing the frontiers of knowledge. For these individuals, contributing to an organization that embodies scientific rigor and innovation offers a unique satisfaction – the knowledge that their legacy will directly fuel the next wave of discoveries. This desire to contribute to something larger than oneself, to leave an indelible mark on the trajectory of human health, is a powerful motivator for legacy giving.
Furthermore, the very act of estate planning is inherently about legacy. It is about thoughtfully allocating resources to reflect one’s values and aspirations for the future. By including CRI in their will, donors are not just making a financial contribution; they are articulating a vision for a future free from the scourge of cancer. This act provides a sense of purpose and continuity, knowing that even after their lifetime, their generosity will continue to empower groundbreaking research and bring hope to millions.
Broader Implications and the Future of Cancer Immunotherapy
The consistent flow of funding from legacy gifts is instrumental in sustaining the long-term, often arduous, journey of scientific discovery. Unlike annual donations that support immediate needs, bequests can contribute to endowments or special funds that provide a stable financial bedrock for research programs that span years or even decades. This stability is crucial for addressing some of the most challenging questions in cancer immunotherapy, such as understanding why some patients respond dramatically while others do not, or developing therapies for "cold" tumors that currently resist immune attack.
The future of cancer immunotherapy holds immense promise, with ongoing research exploring combination therapies, personalized vaccine approaches, oncolytic viruses, and advanced cell therapies. Legacy gifts empower CRI to invest in these emerging areas, supporting preclinical research that lays the groundwork for clinical trials and ultimately, new FDA-approved treatments. The long-term implications of these sustained investments are staggering: a reduction in cancer mortality, improved quality of life for survivors, and a significant alleviation of the global healthcare burden associated with cancer treatment. The economic impact alone, from reduced treatment costs and increased productivity of a healthier population, underscores the societal value of this research.
In conclusion, no matter the specific details or size of a bequest, CRI expresses profound gratitude for every contribution directed towards the scientific research conducted by the brightest minds in immunotherapy. These gifts are more than just financial assets; they are declarations of hope, investments in innovation, and catalysts for a healthier future. The Cancer Research Institute extends its sincere thanks to all who consider including CRI in their will or living trust, thereby actively participating in the ambitious yet achievable goal of creating a world immune to cancer. For those with questions about wills and bequests, the office of gift planning at CRI stands ready to assist, reachable at 212-792-5212, providing guidance to ensure that every legacy gift can achieve its maximum potential impact.
